Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903000 | 0.94 | GLP1R (0.49) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL45885 | 0.93 | GLP1R (0.56) | GLP1RNOD1TLR2LPAR3SIRT2 | |
| SCHEMBL16525843 | 0.93 | GLP1R (0.56) | GLP1RNOD1TLR2LPAR3SIRT2 | |
| SCHEMBL15084766 | 0.89 | NOD1 (0.63) | GLP1RNOD1TLR2LPAR3EPHX2 | |
| SCHEMBL22055442 | 0.88 | GLP1R (0.67) | GLP1RNOD1TLR2LPAR3SIRT2 | |
| SCHEMBL14642472 | 0.88 | GLP1R (0.67) | GLP1RNOD1TLR2LPAR3SIRT2 | |
| SCHEMBL22674784 | 0.86 | NOD1 (0.53) | GLP1RNOD1TLR2LPAR3SIRT2 | |
| SCHEMBL24601556 | 0.86 | GLP1R (0.52) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL12680258 | 0.86 | TLR2 (0.56) | GLP1RTLR2 | |
| SCHEMBL13347257 | 0.86 | TLR2 (0.56) | GLP1RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | GLP1R 194/4885NOD1 2672/4885TLR2 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.